take regeneron. here's a classic example of what shouldn't be impacted by petrobas bonds, but will be believe me. earlier this week the ceo came on, the first ceo we had on "mad money." said might show a conclusive benefit by taking regeneron's new drug that lowers your bad cholesterol. competing drug from amgen. but i think regeneron's ahead of amgen's. if the dollar strength causes a deep enough correction, the stock might actually open down on monday morning. even if the data's good. that might be your chance to pounce. we also have a footlocker analyst meeting. now, this is a terrific company. i mean really really well run. and they sell a ton of nike shoes. now, nike reports thursday. so again, let's think this through tactically. if footlocker says things are good for sneakers especially for nike and nike's down because of the strong dollar on monday, that might be a terrific trade. now, i do worry about what's known as nike's futures orders. but think about this as an opportunity. similarly, w

regeneron is now a biotech titan.hey have an excitingeing cholesterol drug coming up later this year. in celebration of this company's meteoric rise let's take a look at leonard schleifer. welcome back to "mad money." >> good to see you. >> good to see you. until you came on a lot of people were thinking i don't know, is it the right place. i thank you. i think you recognized we were open minded. we always liked biotech. you had the vision that this drug was going to be a huge drug. >> we thought if we stuck with the science, we could get there. we didn't know how long it would take and we didn't have a lot of people believed in us. we appreciated that you believed in us when we were a single digit stock. >> the head to heads were so much better than we realized. the people you were taking on -- these are tens of billions of dollars that these companies make and their market gap is gigantic. you were the david to goliath here. >> it is all based on what you do for pashtdtients. this is not the soap business or the clo

the regeneron drug, you don't have to go to the doctor and you can self-inject it and it works.nd so far the health profile is pretty good. why would i say to esperion i have to fast track you when i have something and you guys can take your time. do it right. aren't you afraid that the fda isn't going to do me too with you and rush this? >> i don't think we're looking to rush anything. we are very seasoned drug developers as a team, at esperion. and we have been developing this drug in a very forthright fashion, carefully, but also very quickly. and so we're not looking for the fda to necessarily rush this. we are looking to move it forward, and we had been working cooperatively with fda to do that. what we like to say is that we hold the radical belief that patients will prefer an oral once daily pill rather than having to self-inject or as -- or go to the their doctor for an injection. but i think the convenience of oral dosing is really important to patients who have to take a medicine like this for the rest of their lives if they have elevated ldl cholesterol. >> i want to

i still like regeneron but i can't endorse this stock all the way up here.ently gone into the companies a analyst day this wednesday. the time to buy avalanche was $10 after it got pancaked by the secondary offering. finally last thursday mark in tennessee called in about northwest bio therapeutics. that's a tiny $500 million bio tech. up 41% year to date. it's a development staged bio tech with a platform where they used activated cells to mobilize a patient's own immune system to attack many differ type of cancer. it actually became public in 2001 and collapsed shortly there after. lately the stock has been roaring because they got approval from health canada. a phase three trial, the main drug in patients with brain cancer. at the end of the day i think it's simply too speculative for me. too risky. it's a money losing enterprise that only has 13 million in cash on the balance sheet at the end of december. plus northwest bio has been rebuked by the md anderson cancer center for what they called inappropriate and unjustified claims about the results of an

regeneron coming off, isis. people were earlier on these.en don't keep paying. >> richard fisher once said the fed has given the markets too much ritalin. he's retiring after a decade as president of the dallas fed. a live interview coming up. >>> the dow's up 130. s&p 2103. don't go away. say you're a finance guy. a farmer. a researcher. you used to depend on experience. the internet. your gut. today you can use ibm watson analytics. it can make sense of all kinds of data. uncover hidden correlations and new opportunities. and give recommendations with more confidence on who will buy. what to make. where to plant. which helps you make smarter decisions. there's a new way to work and it's made with ibm. >>> s&p looking on track at least to have gained almost 50 points for the week. you see the dow back above 18k. back above 2100 on the s&p. back above 5000 on the nasdaq. nike above for the first time ever. >> it's really good. once we have the fed out of the way, people are not as bearish about stocks as they were simply because if you have

. >>> incadea pharmaceutical pharmacyclics and regeneron has made me a lot of money in my roth i.r.a.ank you so much. a regular guy like me can do it. i'm young and i did it! i'm living proof. thank you so much. boo-yah, baby! >> we are both regular guys and those are regular stories that i worked on for many many years to develop, including regeneron, which is the first ceo we ever had on this show. a big week for cramerica is indeed right around the corner. starting monday, we'll have some of the best and brightest names in american industry. i cannot believe this list. joining us to celebrate for mmx -- i even have my own little special bull -- that's ten years of bringing wall street to main street and helping you make some sense of the market. but yes, entertain! i admit that. since this is the most interactive show on television, i want to hear your story. what does "mad money" mean to you? why don't you send me a video? we'll share it with the world right here on the show. that video made me so happy. i've been a little depressed of late. i think it's weather-related. just go t

our next guest is in charge of bringing sanofi and regeneron's drug to market.hank you, doctor, for being here. what is the headline? you take it just once every couple of weeks and it will bring down the rick of heart disease, or does it eliminate those problems that we've seen with past statins? >> what we're really excited about what we're developing with prulent with patients high-risk for heart attacks due to their high levels of cholesterol, the bad cholesterol, lll. we've have seen tremendous ability of it to decrease the bad cholesterol in our patient who is are high-risk over the course of long-term trials. so together with our partners at regeneron, we're really excited about think, now my father, i guess he uses lipitor, he has bad knees and apparently lipitor, one of the problems with the statins, they hit you in the joints that is not a good thing. would your drug, would this particular drug have fewer of those kind of bad side-effects than the traditional statins. >> we've specifically studied that type of patient in our study we called alternative

. >> reporter: both regeneron and scripts with pfck 9 inhibitors come out and could lead to lower prices at the offset. >> we've got to get the best price for our clients. we've had great conversations with amgen. we would like the right price at the market. >> reporter: express script highlighted cancer as an area of focus where multiple drugs working in similar ways on or near the market. some have called the tighter pricing environment a paradigm shift for the drug industry and it's likely only to continue. for "nightly business report," i'm me >>> still ahead, the snowden effect and why the fallout from the leaks classified document is still being felt from washington, d.c. to si. >>> the non-profit behind wikipedia plans to file a lawsuit against the national security agency and the justice. the suit challenges the mass surveillance program that first came to light when edward snowden revealed the reach of u.s. surveillance back in 2013. eamon javers has been very busy. following this story and others. he joins us now from washington. good evening, eamon. >> reporter: good evening,

. >>> take a look at shares of regeneron pharmaceuticals popping after positive data for its cholesterolg out of the big cardiology conference. >> not just regeneron but amgen, both up on data presented on their competing cholesterol drugs over the weekend. they both show they reduce levels of so-called bad cholesterol or ldl cholesterol by 60%. but the really exciting finding was they cut the risk of heart attack, stroke, and other card vascular effects in half. the drugs are expected to be approved over the summer and they could each draw $5 billion in sales. next we're looking ats a tra zen ka. they found a drug lowered a risk when taken over the long term over aspirin but it raised the risk of bleeding. astrazeneca is trading up a bit today. and edwards, medtronic, and boston scientific are the ones to watch. jpmorgan declaring edwards the winner out of the conference with data out on its heart valve. boston scientific getting a boost from fda approval friday of it's device for atrial defibrillation. >> going back to the cholesterol lowering drugs this is a huge market for these comp

. >> whether it was regeneron, pepsi, starbucks, now a show as you said to be proud of. >> thank youmuch. she has generated the highest growth of the traditional consumer package companies. good for you does matter. i was at a super bowl party. they had humus. >> burger king today, taking soda off the kid's menu. >> amazing. that's what she identified and talked when nelson pelt's person comes in he may like the combination of food and beverage. howard schultz comes on coming from the roastry where he's doing craft coffee. and the stock was at $4.74, he came on he said look i've got a drug that does better than what lucentis is doing, it was a miracle drug. say 423 points later he turned out to be right. >> not bad. what stocks over ten year "mad money" viewers will take that every single day. >> you have a hanes bottom a good buy. >> on this date in '09. >> you can say, you know what? this dollar's going to kill the peso in mexico or you can look back at say, which is today's regeneron? which is the company today that's going to get thrown away because of the real? the real? >> yes.

this weekend regeneron, said this could be a one of breakout cholesterol news.ieve might be a one a day pill for people who -- for bad cholesterol. and i want to see that data. i know meg tirrell's all over. regeneron's having a breakout here. >> there's a one a day pill for cholesterol. it's called tolerate nevercor. >> if they don't work. millions of people they don't work, david, and this might be the answer. >> have we proved in fact it is important to have cholesterol down? >> they felt that in the 80s, they didn't think it was. in the 90s it was. bad cholesterol is bad. >> it's bad. >> bad is bad. you know what i mean? >> high ldl -- >> i don't know. check your watch. check your watch. what does your watch say? >> i don't have a watch. >> you don't have an apple watch. >> waiting for that one to pass over to me. >> i'm passing it over to you. >> passover. moses will decree it. >> jim, 46 and change on crude you still think 42. >> i think 42 holds. relying on rich kinder who is so much better than i am, knows so much has the national pipeline, feels that's

. >> regeneron, pcsk 9, the anti-bed cholesterol inhibiter, we'll see data this weekend that i thinkpositive. this is the $17 billion market according to deutsche bank. it's big. those of us who can't take the statins or those of who it's not the statins aren't working well enough they're the stand around this is what -- the karmchairman -- >> is there a -- >> gigantic worldwide. the ceo of merck when they did love va statin and the chairman of regeneron, people are saying they've got the magic bullet for anti-cholesterol. >> something more widely prescribed? >> is it like one-day vitamin? conceivable. enhas to get the -- >> i takely. lipitor. i don't know if it works. >> you have to pop it if you go to barkley prime. always pop it. richard daly told me that. used to be commerce. >> doesn't really help to pop it with the steak. red wine, though, very good. opening bell five minutes away on this very busy wednesday. stay with us. we're back right after this. ( yawn ) bulldog: i just had a dream i was at mattress discounters with tempur-pedic and the largest selection of memory foam ma

yes, the regeneron data is amazing. to have hit a rock 'em sock 'em alzheimer's drug. yes, the isis formulation, all 13 of them are very exciting. yes, i believe in receptos. yes, i like the future of immunotherapy. nevertheless, i love profits. i love making money. and a lot of money has been made. why not ring the register on some so you can try to play with some of the house's money? and not just your own. the bottom line no one has ever made a mistake taking a fat profit in the ten years i've been doing this show. and if you buy them here and you blame me then you are sorely wrong and have lost all focus. focus bag code word for you're a real chowder head. stay with cramer. attention investors!s! vectorvest mobile is here and it's free! make faster, smarter better trading decisions with ctorvest mobile. the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes ranks and graphs... ...over 16,000 stocks worldwide, everyday,... ...and gives you clear buy, sell, hold re

everyone is excited about icare because of regeneron. i like this stock. i think it's good.s a decent speculation. bob in california. bob? >> caller: booyah, jim. thank you for everything you do for us. >> thank you. >> caller: i have a question on union pacific. it was down 4% yesterday. on news from kansas city southern. >> well, ksu they had oil and the peso. i think union pacific, 112 you buy some then and then at 108. i like it. that, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. ♪ >>> earlier i month i had a chance to walk and talk to the ceo of honeywell. he showed us the in flight wi-fi technology. take a look. >> this is a very ugly looking product. but it's going to allow you to be on a plane and be connected to every place in the world, via satellite. it's 100 times faster than what exists today and it's 50% less expensive. >> so if honeywell can potentially make your inflight wi-fi 100 times faster, half the cost, i think that's big deal for gogo. the number one purveyor

they're made by amgen, and regeneron and pfizer. this week amgen will present data on howell its drug does at reducing the risk of heart attacks and other risks. regeneron and sandfi. fooiz pfizer is competing in the space. they're expected to talk about rejenner rons and amgen's next week. actelion will have a drug for pulmonary hypertension. celexopag will be on the market. the data we see over the weekend could have implications for both of those stocks. lots of activity in both drugs and medical devices at the cardiology conference. it's clearly hard at work on our heart. >> no one pronounces those drugs better than you do. >> i stay up at night. >> sarah, down to you. >> got a big story coming up. robert frank that sounds like a juicy one. >> sara this has everything an arrest in monaco secret storage bunkers, money laundering and billionaires who say they've been defrauded. it's tripping the art world coming up next. >>> welcome back to "power lunch." we want to draw your attention to the market. we are taking a look at the ma

but then there's regeneron, up another 16 points today off its new cholesterol drug. ors or esperrion. positive clinical trial data on that cholesterol pill sent the stock soaring 29% today. an astonishing move. esperion tweeted it was going to come on, but canceled at the last minute because it filed an equity offering to take advantage of the stock's strength. then there's activist a giant drug company that closed on its acquisition of cramer fave allergan earlier today. the key thing you know about activist, it's a growth plan that's not known by the same rules that pfizer or lily play for, which is why it rallied up $2.50 why the old line pharmas didn't do so hot. now, again, before this year before this year started, we didn't see this kind of disparity within various groups. it was very rare to see a biotech diverge from the older drug companies, it used to lead them up. but that's not the norm in 2015. we're back at that $43 level, where rich kinder the fave of kinder morgan came on our show and said there's actual demand that we could bounce. last time we boun

larger biotech stocks within the s&p 500, individually speaking, if you watch shares of biogen, regeneron, amgen, you can see down around by a quarter to 1% they're trying to move higher now, relative outperformer has been gilead sciences which as you can see up by a third of a perce percent. for that context many stocks hit historic highs within the last three to six months. this is a large pull back, possibly a value creation event but still uptick over the medium to long term. traders want to dabble in this move lower back to you. >> it's funny. number of firms are out there today defending biotech like you haven't seen. piper, biotech valuation concerns they say misguided. s&p capital iq, bioteches have more room to run. i reached out to isi's dr. mark shownbone. one day move. call me in a month. are we making too much of what's taking place in biotech. >> biotech is by definition more volatile and expensive than the rest of the market and always go to be the case and showboun has been on tv, came on cnbc when janet yellen made the overvalue case. >> we had him on the show. >> the big

general growth properties, regeneron pharmaceuticals, under armour, netflix, united rentals could notat six years for everybody. the worst performers are transocean avon diamond offshore drilling, first solar and the retail investors who completely missed out. stephanie: did you have hair sixers ago? -- six years ago? matt: i did. i was starting to lose it but it was still an exciting mop of blondish -- stephanie: we got to move on. the private equity world is moving fast and no one knows that more than the partner overseeing pe in the americas. some say that he could take over as ceo. bloomberg news editor-at-large jason kelly sat down with navab for an exclusive interview. besides the fact that over the last two decades he got a whole lot richer what has he changed about the private equity business? jason: this is a radically different business from what alex joined in 1993. kkr had a handful of partners and they only did private equity . probably the biggest change for the firm, other than being publicly traded and much more global and being much larger, is that they are in differe

now this new drugs to control cholesterol from amgen and regeneron showing signs they can cut heart riskshalf. heart disease is the world's number one killer. look at the share price of those companies right now, all up very nicely, thank you. >>> here's what else we have for you. elon musk has got people talking again. sent out a tweet, big announcement coming later this week. looks like a new plan to extend battery life on his cars. do you buy the stock on elon musk turns to twitter to stimulate buzz and when gas prices keep on falling? we'll have an answer next hour. >>> weddings, whoa, getting much more expensive. according to the knot.com, the average is $31,000. that's nationwide. much higher in manhattan. off the charts here. we'll talk to the editor-in-chief of the knot 12:15 eastern today. we have some gee whiz tech for you later on, the device that claims to cut a baby's crying by 50%. [laughter] i have some experience in this. not sure i'm going to buy that but we are talk to the creator. >>> here's the story that's really creating the buzz, the big money celebrity real estate

actavis, regeneron. >> malloncot is cheaper than actavis.look at that thing. that is humming. it was much much lower. it's going higher. it's undervalued considering traditional pharma. >> say hello to tim tebow. >> on the scout team for five minutes. >> an open mind what everybody says about chip. "mad money," 6:00 p.m. simon's here to tell us what's coming up next. >>> big moves, keep everybody up to speed. lower for longer but case against near-term rally in oil. apple tv look like it's the talk of the summer. we'll have analysis. and the logic that art cashin says janet yellen is about to em employ on two days of fomc. hour two on "squawk on the street." say you're a finance guy. a farmer. a researcher. you used to depend on experience. the internet. your gut. today you can use ibm watson analytics. it can make sense of all kinds of data. uncover hidden correlations and new opportunities. and give recommendations with more confidence on who will buy. what to make. where to plant. which helps you make smarter decisions. there's a new way

. >> and amgen and regeneron and humana. a lot of them -- >> thank you. >> edwards life science is leading the pack. >> breaking news on hbo right now. julia boorstin in los angeles with details. julia? >> thanks so much. i'm in austin at south by southwest but this news is all about hbo and cablevision. hbo and cablevision announcing that cablevisions optimum online internet service will be the first internet service to package together hbo now, the new over the top streaming service that hbo recently announced would be launching in april with apple. now, apple has the exclusive streaming rights to hbo now, but when it comes to the regular cable and satellite tv providers that are already distributing hbo, cablevision is the first to announce that it will be bundling that standalone service with its internet service. so you no longer have to pay for a whole tv package to cablevision if you want to watch hbo. you could pay for high speed broadband and add on hbo to that. we're waiting for details on the launch date for hbo n

regeneron last week. so i like both of those. collision avoidance in your car. it's very interesting. goldman went hold the buy last week. goldman's the lead manager in the 14.5 million shares and goldman is also sharing shares. it's a very goldman day. >> yes. >> isn't that terrific? >> speaking of being in your car, we should mention garrman. >> you know you love your garman, but now you hook up your iphone it tells you pretty much what garman is going to tell you. >> this cardiology conference. met >> he knows better than anyone. they have a device that makes you not have to crack open the chest cavity. it's going to keep winning. edwards has been the real winner. their scientific editor. ew you're not going to go wrong. i think eventually e.w. gets acquired. it is such an amazing company. i really love these guys. they've been on they are terrific. they're the technological leader. the doctors love them. and they're great guys. >> yeah all the action around heart valves this week. >> and then cardiology is going to save lives. it's really terrific. as you ge

even regeneron. hey, give us a chance here. let it cool. there's nothing wrong with that. other places to go. >> noted. mankind, by the way, the worst performer over the past month. >> that is not working. their breathalyzer is not really working. i want to get the right use for that, but i have to tell you that mankind is not the place. >> let's move on to the company that we're drinking. starbucks announcing that its baristas will no longer be asked to write "race together." the coffee chain will continue other aspects of its campaign aimed at sparking discussions about race. just days ago on a fine program you may have heard about called "mad money," he defended his company's race together initiative. >> a.l. all we're doing is potentially do something catalytic to start a discussion. we're simply trying to raise the awareness, the level of empathy and compassion necessary to bridge the cultural divide that exists in this country today. if a customer or a barista wants to opt out of it it is not mandated. it's simply an act of kindness. >> so that ends now. whatever you

." >> insanity in the market like regeneron, you can shoot yourself with that for the anti-cholesterolgenitic, big alzheimer's news come out on friday. every day the stock goes up. today another analyst, credit suisse raising price target. it's going up again tomorrow. whether it be receptos fold they have positive regulatory approval, celgene breaking out and biogen goes up. >> people making jokes about yellen covering her biotech sword yesterday. >> i did make that joke. not respectful joke. she's doing a good job. >> watch starbucks, goes public jim, in june of 1992 and it's never been higher than at this moment. >> howard shut onchultz on the show last night, don't be cynical. they are doing so many initiatives and taking it to the rest of retail. they are a technology company, they are well-run doing great in china and that's what the, from my point of view i feel like i'm parochial saying it but they're running a great company. >> michael's this morning, a slight hit. we'll talk to the ceo, chuck ruben later today, but cutting outlook. >> retails interesting. vince, i love the sh

froth's coming out of biotech very fast regeneron loses 40 points. is his spear on they're tough to look at they look at a pure parabolic blow-off. it just does not bottom quickly. the difficulty is to find leadership. if gasoline and oil are going up will you lose retail restaurant? it's conceivable. you can lose airlines. there is negative semiconductor news, and biotech is weighing on so where do people go? and that's why did the futures rally? i think it's arguably people are going back to the j&j syndrome back to bristol-myers. i just -- we're lacking leadership. the reason we don't go down as hard, yesterday was a very very horrible day. and a lot of the research today is reflecting other than sandisk, what happened yesterday. >> those also saying we shouldn't have been up so much last week. >> right. >> the s&p basically hit its level from the 18th yesterday, so really why were we up last week and now just returning to levels we should have been at because the reaction to the news last week was bizarre. >> we were so happy. the oh the fed, the

we've had the regeneron ceo on. there's going to be some data there.. we should see some data in the late breakers. those are the most important data highlighted at the meeting on the amgen drug and some of the cardiovascular outcomes being seen by lowering the ldl, bad cholesterol, with those inhibitors. those are expected to be approved potentially later this year. as we get more of these to see how they work and not just that they do lower cholesterol, but what outcomes that has in terms of heart attacks and other things associated with high clost cholesterol. that will be a big one to watch. the other that could move stocks monday is a swiss company working in hypertension. this is actually kind of a rare disorder affecting the arteries between the heart and the lungs. they get narrowed. they're working on a drug that could compete with one from united therapeutics. we already saw some data on this drug. phase three in june of last year which drove the stock way up. but we're going to get more granularity on that data. that could have implications

regeneron we've had on a bunch of times. they are saying they're looking to do a fair price.rsations with them. is there a price drug makers could set at the outset where you wouldn't seek a discount? are you guys going to seek a discount regardless of what it is? >> we're going push really hard because we've got to get to the best price for our clients. but the reality is we think the demands is much different. you're exactly right. we're having great conversations with re onron, amgen. so we would really like for the right price to be the price they bring it to the market in. >> dr. miller this brings us back to a conversation we had with you several months ago. i think it's great you're looking at ways to make sure you're getting the best prices for your customers 37 but i still have concerned whether consumers will be able to get the drugs they need that are new to market that are just making sure they have the access to all of those. how do you reassure consumers? >> our goal is exactly what you're saying. i would love not to exclude a single drug. what you'd really like

but also regeneron and american airlines group all up between 8% and 11%.there. becky, if you look at what's happening overall with the market some large cap stocks especially headache have been driving things forward in the s&p over the last week month, and year to date. health care stocks have been the standout. >> thank you. again, dom chu. >>> dallas federal reserve fed president richard fisher had tough words for market participants last week. >> what worries me however, is how lazy investors have gotten. totally dependent on the federal reserve. i find this to be a precarious situation. but all i'm saying is right now in terms of the real economy, we are growing, others are not growing as well as we are. we're still innovateing and inventing. >> let's get one of our squawk market masters to weigh in on this as well. peter fisher is also a senior fellow at the tucks school of business. those are tough words. investors are lazy at this point. would you agree with that? >> no i don't quite agree with it. i see what he's getting at. i think the fed's been